NRD
MYGN icon

Nebula Research & Development’s Myriad Genetics MYGN Stock Holding History

Nebula Research & Development’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,962
Closed -$79.4K – 558
2025
Q2 		$79.4K Buy
+14,962
New +$88.4K 0.01% 930
2024
Q4 		– Sell
-11,443
Closed -$313K – 1039
2024
Q3 		$313K Buy
+11,443
New +$310K 0.04% 701

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nebula Research & Development's MYGN Position: Q3 2025 in Review

Nebula Research & Development sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 14,962 shares — an estimated $79.4K sold.

Nebula Research & Development first reported a position in MYGN in Q3 2024 and held it in 2 quarters. The position peaked at $313K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Nebula Research & Development reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 14,962 Myriad Genetics shares in Q3 2025, an estimated $79.4K.
  • Nebula Research & Development first reported a position in Myriad Genetics in Q3 2024 and held it in 2 quarters.
  • Nebula Research & Development's Myriad Genetics position peaked at $313K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.